

Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein

Daniel Wright^{a,b}, Elizabeth R. Allen^c, Madeleine H.A. Clark^d, John N. Gitonga^a, Henry K. Karanja^a, Ruben Hulswit^c, Iona Taylor^b, Sumi Biswas^b, Jennifer Marshall^b, Damaris Mwololo^e, John Muriuki^e, Bernard Bett^e, Thomas A. Bowden^c, George M. Warimwe^{a,f}

^aKEMRI-Wellcome Trust Research Programme, Kenya, ^bThe Jenner Institute, University of Oxford, UK, ^cWellcome Centre for Human Genetics, Division of Structural Biology, University of Oxford, UK, ^dLondon School of Hygiene & Tropical Medicine, UK, ^eInternational Livestock Research Institute, Kenya, ^fCentre for Tropical Medicine and Global Health, University of Oxford, UK

ABSTRACT

1 Rift Valley fever (RVF) is a viral haemorrhagic disease first discovered in Kenya in 1930.
2 Numerous animal studies have demonstrated that protective immunity is acquired following
3 RVF virus (RVFV) infection, and that this correlates with acquisition of virus neutralizing
4 antibodies (nAb) that target the viral envelope glycoproteins. However, naturally acquired
5 immunity to RVF in humans is poorly described. Here, we characterized the immune response
6 to the viral envelope glycoproteins, Gn and Gc, in RVFV-exposed Kenyan adults. Long-lived
7 IgG (dominated by IgG1 subclass) and T cell responses were detected against both Gn and
8 Gc. However, antigen-specific antibody depletion experiments showed that Gn-specific
9 antibodies dominate the RVFV nAb response. IgG avidity against Gn, but not Gc, correlated
10 with nAb titers. These data are consistent with the greater level of immune accessibility of Gn
11 on the viral envelope surface and confirm the importance of Gn as an integral component for
12 RVF vaccine development.

13 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

14 INTRODUCTION

15 Rift Valley fever (RVF) is one of several epidemic diseases prioritised by the World Health
16 Organization and other global organisations for urgent research and development of control
17 interventions (Mehand et al., 2018, Gouglas et al., 2018). The disease was first described in
18 Kenya in 1930 but RVF epidemics are now commonly reported in Africa and the Arabian
19 Peninsula (CDC, 2020). RVF is caused by the mosquito-borne Rift Valley fever virus (RVFV),
20 a single-stranded RNA *Phlebovirus* in the *Phenuviridae* family (ICTV, 2020). The virus
21 primarily infects ruminants resulting in high rates of neonatal mortality and abortion, that
22 translate to major economic losses in the livestock industry of affected countries. Zoonotic
23 transmission to humans most commonly occurs during livestock epizootics through infectious
24 mosquito bites or direct contact with tissue or fluid from infected animals (Daubney et al.,
25 1931a, Nicholas et al., 2014). A wide spectrum of clinical manifestations characterize RVF in
26 humans; including self-limiting mild illness associated with fever, myalgia and other non-
27 specific symptoms, through to haemorrhagic and neurological manifestations with high case
28 fatality and debilitating sequela, and miscarriage in pregnant women (reviewed in (Wright et
29 al., 2019)). No therapeutics or vaccines are currently approved for human use, though several
30 candidate vaccines are in development (Gouglas et al., 2018).

31

32 RVFV contains a tripartite genome consisting of a small (S), medium (M) and large (L)
33 segment (Wright et al., 2019). The S segment encodes the nucleoprotein (N) and a non-
34 structural protein (NSs). The L segment encodes the RNA-dependant RNA polymerase. The
35 M segment encodes the structural glycoproteins, Gn and Gc. These two glycoproteins form
36 heterodimers arranged into higher order pentamers and hexamers that encapsulate the
37 mature virion and are responsible for host-cell attachment and membrane fusion (Halldorsson
38 et al., 2018a, Freiberg et al., 2008, Sherman et al., 2009, Huiskonen et al., 2009). They are
39 the prime targets of neutralizing antibodies. Through the use of alternative translation sites
40 and post-translational cleavage, the M segment also encodes for a non-structural protein and

41 a 78kDa protein, which may play a structural role in virus-derived from mosquito cells
42 (Weingartl et al., 2014).

43

44 Historical seminal studies in livestock and non-human primates demonstrated that immunity
45 to RVF is acquired following recovery from RVFV infection, and that this can be passively
46 transferred to susceptible animals through administration of convalescent sera (Peters et al.,
47 1988, Daubney et al., 1931b). These studies identified viral neutralizing antibodies (nAb),
48 which target the RVFV Gn and Gc envelope glycoproteins, as the main correlates of protection
49 against RVF (Easterday, 1965). Occupational exposure to RVFV infection during the decades
50 following the discovery of RVFV provided the first evidence of naturally acquired RVFV nAbs
51 and these tended to be long-lived, being readily detectable in two individuals 12 and 25 years
52 post-infection, respectively, despite no further exposure (Smithburn et al., 1949, Brown et al.,
53 1957, Findlay, 1936). However, beyond these studies, naturally acquired immunity to RVFV
54 in humans is poorly described. Here, we sought to address this paucity of information by
55 characterizing the humoral and cellular response to RVFV among naturally exposed adults in
56 Kenya, including an investigation of the longevity and kinetics of RVFV nAbs in this population.

57

58 **RESULTS**

59 Stored samples from two adult populations in coastal Kenya were used for this study (see
60 Methods). One population of adults comprised a random selection of fifty RVFV-exposed
61 individuals included in a previous cross-sectional survey investigating the risk factors for RVFV
62 exposure in Tana River county (Bett et al., 2018). The second population was composed of
63 adults under longitudinal surveillance for malaria within the KHDSS in Kilifi county and had
64 previously not been screened for RVFV exposure (see Methods).

65 **IgG responses against Gn and Gc correlate with RVFV nAb levels**

66 We first measured IgG antibody responses against Gn and Gc in fifty RVFV-exposed adults
67 from Tana River county and assessed their relationship with the RVFV nAb response. The
68 geometric mean titer (GMT) of RVFV nAb as measured by virus neutralizing assay (VNT₅₀) in
69 these fifty adults was approximately 2100 (95% CI 1543, 2792), and ranged between ~160 to
70 >14000 (**Fig. 1**). Total IgG titers against Gn and Gc (ELISA GMT of 67.3 for Gn and 66.9 for
71 Gc) were highly correlated ($r=0.77$, $p<0.001$). A strong correlation was observed between the
72 RVFV nAb titer and IgG response against Gn ($r=0.76$, $p<0.0001$) and Gc ($r=0.68$, $p<0.0001$)
73 (**Fig 1a**). IgG1 subclass predominated the antibody response against both Gn and Gc (**Fig.**
74 **1c**).

75 We also measured the avidity of the antibody response to each glycoprotein, expressing this
76 as the concentration of NaSCN, a chaotropic agent, required to reduce ELISA signal by 50%
77 (NaSCN IC₅₀). Anti-Gc antibody avidity was significantly higher than that for anti-Gn antibodies
78 (**Fig. 1b**); however, a correlation between antibody avidity and nAb response was only
79 observed for Gn ($r=0.37$, $p=0.009$) and not Gc ($r=0.08$, $p=0.57$).

80 **nAbs from naturally exposed adults preferentially target RVFV Gn over Gc**

81 We next investigated the relative contribution of Gn and Gc to the RVFV nAb response. To do
82 this, we pooled sera from 7 RVFV-exposed adults from Tana River county that had sufficient
83 material available. We then depleted the pooled serum of antibodies specific for one or both
84 of the recombinant RVFV glycoproteins (see Methods). ELISA was used to confirm the
85 depletion, showing a reduction in IgG endpoint titer of 98% and 93% for Gn and Gc,
86 respectively, compared to non-depleted serum (**Fig. 2a**). The impact of this antigen-specific
87 antibody depletion on the ability of the pooled serum to neutralize RVFV *in vitro* was then
88 measured by VNT₅₀. Anti-Gn antibody depletion resulted in a 79% reduction in nAb titer
89 compared to the non-depleted serum (**Fig. 2b**). In contrast, depletion of anti-Gc antibodies
90 from sera showed a modest 29% reduction compared to the non-depleted serum (**Fig. 2b**).
91 Depletion of both Gn and Gc antibodies showed a 79% reduction in nAb titer, identical to the
92 pool depleted of anti-Gn antibodies alone (**Fig. 2b**).

93 Of 200 adults under longitudinal surveillance for malaria studies in Kilifi county, 6 (3%) in 2018
94 had evidence of RVFV exposure on the basis of carriage of RVFV nAbs (see Methods). To
95 confirm the predominance of Gn as a target of the RVFV nAb response, we pooled sera from
96 these 6 individuals and repeated the depletion experiment described above and used a focus
97 reduction neutralization assay (FRNT₅₀) to measure RVFV nAbs (see Methods). Results were
98 consistent, showing a relative reduction in FRNT₅₀ of approximately 76%, 14% and 70% in
99 sera depleted of antibodies to Gn, Gc or both, respectively (**Fig. 2c**). These data support RVFV
100 Gn as the major target of the nAb response arising during natural RVFV infection.

101 **IgG and RVFV nAb titers remain high over many years.**

102 To study longevity of the observed immune responses we used three of the six RVFV-exposed
103 adults from Kilifi county that had corresponding stored serum samples spanning multiple years
104 (see Methods). We also included stored sera from an additional two RVFV-exposed adults
105 identified from the same surveillance study in previous years. Overall, the period covered by
106 each individual's samples ranged from 3-11 years, but dates of RVFV exposure were unknown
107 (**Fig. 3**). Both IgG (anti-Gn and anti-Gc) and RVFV nAb titers were readily detected over the
108 period of follow up (**Fig. 3**). In keeping with the two seminal studies on the durability of RVFV
109 nAb titers, the individual from whom we had the highest number of samples, JA0073 (n=8),
110 exhibited high nAb titers over an 11-year period (**Fig. 3a**). RVFV nAb titers were generally
111 stable with only slight reductions from individual peak nAb titers observed. One individual,
112 JA0193, had a >12 fold increase in nAb titer between their baseline sample and the sample
113 collected 5 years later, indicating RVFV re-exposure in the intervening period. Total binding
114 IgG titers towards both glycoproteins were also long-lasting, remaining high despite a gradual
115 decline over the years, while avidity remained stable (**Fig. 3b, c**).

116

117 **RVFV infection elicits a moderately low but significant cellular response to Gn and Gc.**

118 Cryopreserved PBMCs were also available from 5 of the RVFV-exposed adults sampled in
119 2018 from Kilifi county, allowing an assessment of RVFV-specific T cell responses. We
120 measured Gn and Gc-specific IFN γ responses by ELISpot in five individuals and compared
121 these to PBMCs from five randomly selected individuals from the same population who had
122 no evidence of RVFV exposure (on the basis of lacking RVFV nAb or Gn/Gc IgG responses).
123 Overall, the IFN γ response was moderately low in the five RVFV-exposed individuals (mean
124 response 67.4 SFC/10⁶ PBMC 95% CI 6.8-128 SFC/10⁶) but this was significantly higher than
125 non-exposed controls (mean response 8.4 SFC/10⁶ PBMC 95% CI 0-21.7 SFC/10⁶)(**Fig. 4**).
126 Responses among RVFV-exposed individuals were comparable across individual peptide
127 pools (**Fig. 4**). Staphylococcal enterotoxin B (SEB) was used as a positive control for PBMC
128 stimulation and all unexposed and RVFV-exposed individuals had a response >1900 SFC/10⁶
129 PBMC as expected. Together, these data indicate that natural RVFV exposure elicits a durable
130 T cell response.

131

132 **DISCUSSION**

133 The protective role antibodies play against RVFV infection is well documented (Peters et al.,
134 1988, LaBeaud, 2010, Niklasson et al., 1984). The structural glycoproteins displayed on the
135 surface of RVFV, Gn and Gc, are key targets of this protective immune response and
136 monoclonal antibodies have been identified targeting both (Besselaar and Blackburn, 1991,
137 Besselaar-Blackburn, 1992, Wang et al., 2019). However, relatively little is known about the
138 nature and longevity of the immune response after natural RVFV exposure. Here, using
139 samples from adults in coastal Kenya with evidence of previous exposure to RVFV we show
140 that: i) RVFV Gn and Gc glycoproteins are both targets of the long-lived T cell and IgG
141 response to RVFV, and that the antibody response is predominated by the IgG1 sub-class, ii)
142 RVFV nAb titers strongly correlate with Gn and Gc-specific IgG responses, and that iii) Gn is
143 the main target of the RVFV nAb response. We also found that IgG avidity against Gn (but not

144 Gc) correlated with the RVFV nAb response, further highlighting qualitative differences in the
145 antibody response to both glycoproteins.

146

147 Studies in mice and rabbits have identified monoclonal antibodies targeting either Gn or Gc
148 that are able to neutralize virus and confer protection against RVFV challenge (Besselaar and
149 Blackburn, 1991, Besselaar-Blackburn, 1992, Keegan and Collett, 1986, Allen et al., 2018).
150 Initial evidence of the possible greater role that antibodies targeting Gn play in protection, with
151 respect to the Gc, came from reports involving passive transfer of anti-Gn or anti-Gc antibodies
152 in mice, with only anti-Gn providing protection (Battles and Dalrymple, 1988). Another study
153 in mice, this time involving vaccination with Gn- or Gc-coding DNA, showed that those
154 vaccinated with Gn, but not Gc, developed nAbs (Lagerqvist et al., 2009). A more recent study
155 isolating mAbs from a convalescent human patient returning to China found that mAbs specific
156 to Gn exhibited much higher neutralization titers than those that bind Gc (Wang et al., 2019).
157 This provides some evidence, perhaps, that the larger negative impact on neutralization titer
158 seen in our study after depleting antibodies targeting Gn, compared to Gc, reflects a greater
159 neutralizing potential of anti-Gn antibodies rather than merely increased abundance over anti-
160 Gc antibodies. Further evidence supporting this hypothesis can be observed from our
161 measurement of IgG avidity. Higher avidity antibodies can bind antigen more efficiently, and
162 only the higher avidity of anti-Gn antibodies was associated with increased nAb titer. While
163 avidity was very stable over many years, it is typically lower in acute or recent infection.
164 However, due to the sparse sampling (no more than once a year), initial changes in the weeks
165 and months post-exposure are not visible.

166

167 It is important to consider the differences between monomeric and soluble RVFV Gn and Gc
168 used in these assays and their higher order membrane-bound pentameric and hexameric
169 assemblies on the virion surface (Lozach et al., 2011, Leger et al., 2016). While our data
170 shows that dual depletion of both Gn and Gc antibodies reduces nAb titers to identical levels

171 seen in sera depleted of Gn antibodies alone, even dual-depleted sera can neutralize live virus
172 at the highest concentration (**Fig. 2**). While this is likely due, at least in part, to the incomplete
173 nature of the depletion (corresponding ELISA signal post-depletion was not entirely eliminated
174 at high serum concentrations), it is also likely that a subset of antibodies recognize epitopes
175 constituting higher-order quaternary assemblies formed on the native virion surface. These
176 antibodies may be capable of neutralizing whole virus but may not bind monomeric Gn or Gc
177 and therefore would not have been depleted. Nevertheless, we were still able to assess the
178 relative contribution antibodies targeting each individual glycoprotein have on neutralization.
179 While both glycoproteins are clearly immunogenic and targeted by the nAb response, our data
180 suggest that after naturally acquired human infection antibodies targeting Gn, rather than Gc,
181 play a larger role in RVFV neutralization. This is perhaps not surprising considering that the
182 N-terminal component of Gn occupies the most membrane-distal region of the virus, which
183 plays a role in shielding the cognate Gc (Halldorsson et al., 2018a, Allen et al., 2018), and
184 therefore may be more easily accessible to the host immune system (**Fig. 5**).

185

186 While protection against RVFV infection has long been associated with the induction of nAbs
187 targeting Gn and Gc (Dodd et al., 2013, Peters et al., 1988, LaBeaud, 2010), it can also arise
188 from other mechanisms. Mice vaccinated with the immunodominant nucleoprotein (N), for
189 example, show partial protection from RVFV challenge despite the absence of detectable
190 nAbs (Lopez-Gil et al., 2013, Jansen van Vuren et al., 2011). Another study showed the
191 cooperative effect of a non-neutralizing antibody improving protection in a mouse model
192 (Gutjahr et al., 2020). Perhaps more surprisingly, mice vaccinated with modified Vaccinia
193 Ankara (MVA) expressing both Gn and Gc failed to elicit nAbs but were still protected from
194 viral challenge (Lopez-Gil et al., 2020). IgG1, the predominant subclass recognising the RVFV
195 glycoproteins identified here, can efficiently trigger the classical route of complement
196 (Vidarsson et al., 2014). While the contribution that non-neutralizing antibodies and cellular
197 immunity have on protection against RVFV is less well characterized, numerous components

198 of the immune response may function together during acute infection (including experimental
199 challenge in animals) to provide protection. Studies on the immune response during acute
200 RVFV infections in humans are needed to determine the role of other immune mechanisms in
201 disease pathogenesis and protection.

202

203 Due to its extensive anti-viral properties, we have used IFN γ as a broad measure of the cellular
204 response to RVFV in these individuals. The *ex vivo* ELISpot carried out here is a measure of
205 effector memory T cells that are able to secrete IFN γ within hours of re-exposure to antigen
206 (Calarota and Baldanti, 2013). We have shown that these cells, circulating in the peripheral
207 blood, are relatively low in number in humans with historical RVFV infection. However, they
208 are still detectable in the majority of individuals many years after exposure and they may
209 potentially play an important role in protection. Recently, the T cell responses in human
210 volunteers vaccinated with multiple doses of a formalin-inactivated RVF vaccine were
211 characterized (Harmon et al., 2020). Despite also showing a generally low cellular response,
212 IFN γ expression post-stimulation with Gn, Gc and N peptides were detected by ELISpot many
213 years post vaccination. A previous study exploring the cellular response to RVFV in a non-
214 human primate model have shown that non-lethal challenge was associated with early
215 proliferation of CD4 $^{+}$ and CD8 $^{+}$ T cells in addition to early Th1 cytokine production, including
216 IFN γ (Wonderlich et al., 2018). Another study in humans showed higher expression of IL-10,
217 an anti-inflammatory cytokine, was associated with fatal cases (McElroy and Nichol, 2012).
218 These findings, together with the critical role CD4 $^{+}$ T cells play in generating strong antibody
219 responses (Dodd et al., 2013), indicate the importance and benefit of a robust cellular
220 response.

221

222 Due to the presence of high-titer, long-lived nAbs, it is plausible that the naturally acquired
223 immune response to RVFV may be sufficient for long-lasting protection, particularly as nAbs
224 are associated with protection in animals. The observation that antibodies targeting Gn play a

225 comparatively larger role in neutralization than those that target Gc has potential implications
226 for vaccine design and is suggestive that the Gn may be the most critical antigen to include in
227 RVFV candidate vaccines.

228

229 In summary, while our immunological assessments of individuals naturally exposed to RVFV
230 provide useful data on immunity to infection, there is a lot that we do not know regarding their
231 previous RVFV exposure; when or how often they became infected prior to sample collection,
232 the route of exposure (mosquito bite vs contact with infected animal tissue) and their clinical
233 manifestations. All of these factors will have likely influenced their subsequent response to
234 RVFV and further work is needed to connect immunological attributes with clinical outcomes
235 and disease severity. We have provided data characterizing the immune response in a large
236 number of naturally exposed Kenyan adults who are likely protected from re-exposure. These
237 data can provide a useful benchmark for immune responses elicited in future clinical trials of
238 candidate vaccines.

239

240 **MATERIALS AND METHODS**

241 ***Study population***

242 A cross-section of randomly selected households in Tana River County, Kenya (2013-2014)
243 were enrolled after consenting and all human subjects within that household were sampled as
244 part of a previous study estimating RVFV exposure (Bett et al., 2018). For this analysis, serum
245 samples from 50 individuals were selected at random for antibody characterization from those
246 identified as RVFV-exposed on the basis of seropositivity by both RVFV neutralization assay
247 (VNT₅₀ >10) and a diagnostic ELISA kit (BDSL, National Institute for Communicable Diseases,
248 Centre for Emerging and Zoonotic Diseases, Johannesburg, South Africa) (Paweska et al.,
249 2005). A further 7 RVFV-exposed individuals from the same study and with sufficient material
250 available were assessed in the antibody depletion assays. Serum and peripheral blood

251 mononuclear cells (PBMCs) were available from 200 adults under longitudinal surveillance for
252 malaria studies in Kilifi County in 2018. For some of these adults, serum samples were
253 available dating back to 1998 when they were enrolled into the longitudinal cohort. Additional
254 screening of the serum samples collected in 2013-2014 identified positive individuals not
255 sampled in 2018. Blood samples were collected in plain vacutainers and serum harvested
256 after centrifugation at 3,000 RPM for 5 minutes, before storage at -80°C until use. Heparinised
257 blood was used for PBMC isolation using standard protocols (Illingworth et al., 2013) and
258 PBMCs cryopreserved until use. Ethical approval for this study was provided by the Kenya
259 Medical Research Institute Scientific and Ethics Review Unit (SSC 3296), and the African
260 Medical Research Foundation's Ethics and Scientific Review Committee (approval number
261 P65-2013).

262 ***Protein Expression***

263 ***RVFV Gn:*** cDNA of the Gn ectodomain (UniProt accession number P21401, residues 154-
264 560) was cloned into pHLSec mammalian expression vector, which encodes a C-terminal
265 hexa-histidine tag (Aricescu et al., 2006). Human embryonic kidney cells (HEK293T, ATCC
266 CRL-1573) were transiently transfected and cell supernatants were purified by immobilized
267 nickel-affinity chromatography (IMAC), using 5 mL HisTrap FF crude column and AKTA FPLC
268 system (GE Healthcare). Gn protein was further purified by size exclusion chromatography
269 (SEC) using a Superdex 200 10/300 Increase column (GE Healthcare) into 10mM Tris-HCl,
270 150mM NaCl, pH 8.0.

271

272 ***RVFV Gc:*** cDNA of the Gc ectodomain (UniProt accession number P21401, residues 691-
273 1120) linked to an N-terminal SUMO tag, which also encodes a hexa-histidine tag, was
274 subcloned into the pURD expression vector to generate a stable cell line in HEK293T cells
275 (Seiradake et al., 2015). Cells were harvested after 5 days and RVFV Gc was purified from
276 clarified cell supernatant by IMAC. The SUMO-tag was cleaved with 3C protease (Pearsons)
277 overnight at room temperature. Cleaved RVFV Gc was purified from the SUMO-tag by IMAC.

278 The flowthrough containing Gc was further purified by SEC using a Superdex 200 10/300
279 Increase column (GE Healthcare) into 10mM Tris-HCl, 150mM NaCl, pH 8.0.

280

281 ***Total IgG enzyme linked immunosorbent assays (ELISAs)***

282 96 well NUNC flat bottom plates (ThermoFisher) were coated with 50 µl/well of Gn or Gc at a
283 concentration of 1 µg/mL in carbonate bicarbonate buffer (Sigma) and incubated overnight at
284 room temperature (RT). Plates were washed 6x with phosphate buffered saline containing
285 0.05% Tween20 (PBS/T) followed by blocking with 100 µl/well of casein (ThermoFisher) for 1
286 hour at RT. Plates were then tapped dry and test sera was diluted 1:100, 1:400 or 1:800 in
287 casein. 50 µl/well was added to duplicate wells and incubated for 2h at RT. A positive
288 reference serum made from a pool of high responders (using raw OD₄₅₀ as measured by initial
289 Gn/Gc ELISAs) was included on each plate as a standard curve. This was serially diluted in
290 2-fold steps from 1:100 to 1:51,200 in casein. Each dilution was added to the plate in duplicate,
291 with the 1:100 dilutions given an arbitrary value of 10 RVFV antibody units (AU). Plates were
292 washed as before and 50 µl/well of secondary antibody (goat anti-human whole IgG
293 conjugated to HRP, Insight Biotechnology) was diluted 1:1,000 in casein and added to the
294 plate for 1h at RT. Plates were washed a final time and developed by adding 100 µl/well of
295 TMB developer (Abcam). After 8 minutes incubating in the dark at RT, 100 µl TMB stop
296 solution (Abcam) was added. The optical density (OD) was read at 450 nm using a Varioskan
297 flash reader. OD values were fitted to a 4-Parameter logistic model (Gen5 v3.09, BioTek)
298 standard curve. An internal control of positive serum was included on every plate in duplicate
299 made up from a 1:800 dilution of the positive standard. Test sera arbitrary units (AU) were
300 calculated from their OD values using the parameters estimated from the standard curve.

301

302 ***IgG avidity ELISAs***

303 Total IgG avidity was determined by sodium thiocyanate (NaSCN) displacement, as described
304 previously (Biswas et al., 2014). Briefly, sera was individually diluted in casein to normalise
305 titers, according to their total IgG ELISA AU. Plate coating, blocking and development were
306 performed the same as their respective total IgG ELISAs.

307

308 ***IgG Subclass ELISAs***

309 IgG subclass ELISAs were performed as per the total IgG ELISAs with the following
310 exceptions: Secondary antibodies (biotin conjugated mouse anti-human IgG1, IgG2, IgG3 or
311 IgG4 [Bio-Rad]) were incubated for 1h. After washing, 50 µL/well of eXtravidin-ALP (Sigma),
312 diluted 1:5,000 in casein was added for 1h. Plates were washed and then developed by adding
313 50 µl/well of 4-nitrophenyl phosphate in diethanolamine buffer (Pierce). OD was read at 405
314 nm.

315

316 ***Virus Neutralization assays (VNT and FRNT)***

317 VNT: The dilution required to reduce neutralization by 50% (VNT₅₀) was calculated, as
318 described previously (Lopez-Gil et al., 2013). Briefly, sera pools were diluted in DMEM
319 containing 10% FCS (D10) across a 96-well plate before addition of 100 TCID₅₀ of RVFV MP-
320 12 strain. Sera and virus were incubated at 37 °C for 1h in 200 µl before being added to a 96
321 well tissue culture (TC) plate containing a confluent monolayer of VERO cells. Plates were
322 incubated at 37 °C for 72h before cells were fixed in PBS containing 10% formaldehyde for 1h
323 and stained with PBS containing 1% crystal violet (Sigma) for 10 minutes. Plates were washed
324 with water and left to dry before being scored by eye. Focus reduction neutralizing test (FRNT):
325 This was carried out as previously described (Barsosio et al., 2019) with some alterations.
326 Briefly, serum was diluted in 2-fold steps in triplicate from a starting dilution of 1:20.-
327 Approximately 100 focus-forming units of RVFV (MP-12 strain) was added to each well and
328 incubated for 1h at 37 °C before transferring mixture to 96-well Tissue Culture plate containing

329 Vero E6 monolayers at 90% confluency. After 2h at 37 °C, virus/serum was removed and
330 replaced with media. Plates were incubated a further 48h at 37 °C. Virus foci were detected
331 by adding 1:1000 dilution of Anti-Gn 4D4 mouse mAb (bei resources, Cat. No. NR-43190)
332 followed by 1:1000 dilution of horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG
333 antibody (Abcam, Cat. No. ab6789). After addition of 3,3'-diaminobenzidine (Sigma) substrate
334 for 10 minutes at room temperature, the plates were washed a final time and air dried. Foci
335 were counted using an AID ELISpot reader. Serum dilution required to reduce virus foci by
336 50% compared to virus-only control wells (6 replicates) were calculated from a 4-parameter
337 standard curve using GraphPad Prism version 8 (GraphPad Software Inc., California, USA).

338

339 ***Gn and Gc specific antibody depletion***

340 In order to deplete anti-Gc and/or anti-Gn IgG, 96-well NUNC ELISA plates were coated with
341 5 µg/mL of recombinant Gn or Gc or carbonate-bicarbonate buffer alone. Plates were
342 incubated overnight. After washing with PBS/T as previously described, plates were blocked
343 with 200 µL/well of 1% casein in PBS (Sigma) for 2h. Neat pooled human sera was diluted
344 1:50 in DMEM containing 2% L-glutamine and 1% penicillin/streptomycin (D0) with
345 subsequent 1:2 titrations up to 1:102400. Diluted sera was added to each antigen-coated plate
346 (including the blocked but uncoated control plate) and incubated on a plate rocker at 10 RPM
347 for 4h at room temperature. Serum was then removed and the depletion step repeated once
348 more on additional coated and blocked plates. For the dual Gn/Gc depletion, serum was
349 depleted twice on Gn-coated plates and twice on Gc-coated plates. Reduction of antigen-
350 specific antibodies after final depletion was confirmed by ELISA. Serum was diluted 1:2 with
351 Casein and total IgG ELISA was carried out as described. The endpoint titer is defined as the
352 interpolated dilution (OD at 450nm versus dilution of serum) at which the OD of the sample is
353 0.15. The remaining serum was added to the VNT plate to determine nAb titer, as previously
354 described, with final serum concentrations ranging from 1:200-1:102,400 (Barsosio et al.,
355 2019).

356

357 ***Ex-vivo* IFN γ ELISpot**

358 264 15mer peptides overlapping by 11 amino acids, covering the Gn-Gc polyprotein (Genbank
359 accession number DQ380208, residues 132-1197) were synthesised (Mimotopes). Peptides
360 were split into 5 pools of 52/53 peptides each at 1.25 μ g/mL final concentration. ELISpots were
361 carried out as previously described (Kimani et al., 2014). Responses from unstimulated wells
362 were subtracted before quantifying the response to the 5 pools and summing them. Positive
363 control wells were stimulated with SEB at 0.02 μ g/mL.

364

365 ***Statistical analysis***

366 Statistical analysis was carried out using GraphPad Prism version 8 (GraphPad Software Inc.,
367 California, USA). All analyses of correlations were performed using non-parametric
368 Spearman's correlation tests using a two-sided p value < 0.05 as the cut-off for statistical
369 significance. Comparisons between two groups were analysed using Kruskal-Wallis test or
370 unpaired T-test.

371

372 **AUTHOR CONTRIBUTIONS**

373 Conceptualization D.W., G.M.W. and T.A.B.; Methodology, D.W., E.R.A., J.N.G., H.K.K.
374 G.M.W; Investigation, D.W., M.H.A.C., J.N.G., H.K.K.; Resources, R.H., I.T., S.B., E.R.A.,
375 D.M., J.M., B.B.; Writing – Original Draft, D.W; Writing – review editing, G.M.W., T.A.B.;
376 Funding acquisition, G.M.W., T.A.B; Supervision; G.M.W., T.A.B.

377

378 **DECLARATION OF INTERESTS**

379 The authors declare no competing interests.

380

381 **ACKNOWLEDGEMENTS**

382 This work was supported through grants from the Wellcome Trust (grants no. 203077/Z/16/Z
383 and 203141/Z/16/Z), an Oak foundation fellowship to GMW, and by the Medical Research
384 Council (MR/L009528/1m MR/S007555/1, MR/N002091/1 to T.A.B.). This manuscript was
385 submitted for publication with permission from the Director of the Kenya Medical Research
386 Institute.

387

388 **REFERENCES**

- 389 Allen, E. R., Krumm, S. A., Raghwani, J., Halldorsson, S., Elliott, A., Graham, V. A., Koudriakova, E.,
390 Harlos, K., Wright, D., Warimwe, G. M., et al. 2018. A Protective Monoclonal Antibody Targets a Site
391 of Vulnerability on the Surface of Rift Valley Fever Virus. *Cell Rep*, 25, 3750-3758.e4.
- 392 Aricescu, A. R., Lu, W. & Jones, E. Y. 2006. A time- and cost-efficient system for high-level protein
393 production in mammalian cells. *Acta Crystallogr D Biol Crystallogr*, 62, 1243-50.
- 394 Barsosio, H. C., Gitonga, J. N., Karanja, H. K., Nyamwaya, D. K., Omuoyo, D. O., Kamau, E., Hamaluba,
395 M. M., Nyiro, J. U., Kitsao, B. S., Nyaguara, A., et al. 2019. Congenital microcephaly unrelated to
396 flavivirus exposure in coastal Kenya. *Wellcome Open Res*, 4, 179.
- 397 Battles, J. K. & Dalrymple, J. M. 1988. Genetic variation among geographic isolates of Rift Valley fever
398 virus. *Am J Trop Med Hyg*, 39, 617-31.
- 399 Besselaar-Blackburn 1992. The synergistic neutralization of Rift Valley fever virus by monoclonal
400 antibodies to the envelope glycoproteins.
- 401 Besselaar, T. G. & Blackburn, N. K. 1991. Topological mapping of antigenic sites on the Rift Valley
402 fever virus envelope glycoproteins using monoclonal antibodies. *Arch Virol*, 121, 111-24.
- 403 Bett, B., Lindahl, J., Sang, R., Wainaina, M., Kairu-Wanyoike, S., Bukachi, S., Njeru, I., Karanja, J.,
404 Ontiri, E., Kariuki Njenga, M., et al. 2018. Association between Rift Valley fever virus seroprevalences
405 in livestock and humans and their respective intra-cluster correlation coefficients, Tana River County,
406 Kenya. *Epidemiol Infect*, 1-9.
- 407 Biswas, S., Choudhary, P., Elias, S. C., Miura, K., Milne, K. H., De Cassan, S. C., Collins, K. A., Halstead,
408 F. D., Bliss, C. M., Ewer, K. J., et al. 2014. Assessment of humoral immune responses to blood-stage
409 malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and
410 natural exposure. *PLoS One*, 9, e107903.


- 411 Brown, R. D., Scott, G. R. & Dalling, T. 1957. Persistence of antibodies to Rift Valley fever in man. *The*
412 *Lancet*, 270, 345.
- 413 Calarota, S. A. & Baldanti, F. 2013. Enumeration and characterization of human memory T cells by
414 enzyme-linked immunospot assays. *Clinical & developmental immunology*, 2013, 637649-637649.
- 415 Cdc. 2020. *Rift Valley Fever (RVF) Outbreak Summaries* [Online]. Available:
416 <https://www.cdc.gov/vhf/rvf/outbreaks/summaries.html> [Accessed 20th July 2020].
- 417 Daubney, R., Hudson, J. R. & Garnham, P. C. 1931a. Enzootic hepatitis or rift valley fever. An
418 undescribed virus disease of sheep cattle and man from east africa. *The Journal of Pathology and*
419 *Bacteriology*, 34, 545-579.
- 420 Daubney, R., Hudson, J. R. & Garnham, P. C. 1931b. Enzootic hepatitis or Rift Valley fever. An
421 undescribed virus disease of sheep, cattle and man from east africa. *J. Pathol. Bacteriol*, 34, 545-79.
- 422 Dodd, K. A., Mcelroy, A. K., Jones, M. E., Nichol, S. T. & Spiropoulou, C. F. 2013. Rift Valley fever virus
423 clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific
424 antibody responses. *J Virol*, 87, 6161-71.
- 425 Easterday, B. C. 1965. Rift valley fever. *Adv Vet Sci*, 10, 65-127.
- 426 Findlay, G. M. 1936. The Mechanism of Immunity in Rift Valley Fever. *Wellcome Bureau of Scientific*
427 *Research*, 89-104.
- 428 Freiberg, A. N., Sherman, M. B., Morais, M. C., Holbrook, M. R. & Watowich, S. J. 2008. Three-
429 dimensional organization of Rift Valley fever virus revealed by cryoelectron tomography. *J Virol*, 82,
430 10341-8.
- 431 Gouglas, D., Thanh Le, T., Henderson, K., Kaloudis, A., Danielsen, T., Hammersland, N. C., Robinson, J.
432 M., Heaton, P. M. & Røttingen, J.-A. 2018. Estimating the cost of vaccine development against
433 epidemic infectious diseases: a cost minimisation study. *The Lancet Global Health*, 6, e1386-e1396.
- 434 Gutjahr, B., Keller, M., Rissmann, M., Von Arnim, F., Jackel, S., Reiche, S., Ulrich, R., Groschup, M. H.
435 & Eiden, M. 2020. Two monoclonal antibodies against glycoprotein Gn protect mice from Rift Valley
436 Fever challenge by cooperative effects. *PLoS Negl Trop Dis*, 14, e0008143.
- 437 Halldorsson, S., Li, S., Li, M., Harlos, K., Bowden, T. A. & Huiskonen, J. T. 2018a. Shielding and
438 activation of a viral membrane fusion protein. *Nat Commun*, 9, 349.
- 439 Halldorsson, S., Li, S., Li, M., Harlos, K., Bowden, T. A. & Huiskonen, J. T. 2018b. Shielding and
440 activation of a viral membrane fusion protein. *Nature Communications*, 9, 349.
- 441 Harmon, J. R., Barbeau, D. J., Nichol, S. T., Spiropoulou, C. F. & Mcelroy, A. K. 2020. Rift Valley fever
442 virus vaccination induces long-lived, antigen-specific human T cell responses. *NPJ Vaccines*, 5, 17.
- 443 Huiskonen, J. T., Overby, A. K., Weber, F. & Grunewald, K. 2009. Electron cryo-microscopy and single-
444 particle averaging of Rift Valley fever virus: evidence for GN-GC glycoprotein heterodimers. *J Virol*,
445 83, 3762-9.

- 446 Ictv. 2020. *International Committee on Taxonomy of Viruses (ICTV)* [Online]. Available:
447 <https://talk.ictvonline.org/taxonomy/> [Accessed 21st July 2020].
- 448 Illingworth, J., Butler, N. S., Roetynck, S., Mwacharo, J., Pierce, S. K., Bejon, P., Crompton, P. D.,
449 Marsh, K. & Ndungu, F. M. 2013. Chronic exposure to *Plasmodium falciparum* is associated with
450 phenotypic evidence of B and T cell exhaustion. *Journal of immunology (Baltimore, Md. : 1950)*, 190,
451 1038-1047.
- 452 Jansen Van Vuren, P., Tiemessen, C. T. & Paweska, J. T. 2011. Anti-nucleocapsid protein immune
453 responses counteract pathogenic effects of Rift Valley fever virus infection in mice. *PLoS One*, 6,
454 e25027.
- 455 Keegan, K. & Collett, M. S. 1986. Use of bacterial expression cloning to define the amino acid
456 sequences of antigenic determinants on the G2 glycoprotein of Rift Valley fever virus. *J Virol*, 58,
457 263-70.
- 458 Kimani, D., Jagne, Y. J., Cox, M., Kimani, E., Bliss, C. M., Gitau, E., Ogwang, C., Afolabi, M. O., Bowyer,
459 G., Collins, K. A., et al. 2014. Translating the immunogenicity of prime-boost immunization with
460 ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. *Mol Ther*, 22, 1992-
461 2003.
- 462 Labeaud, D. 2010. Towards a safe, effective vaccine for Rift Valley fever virus. *Future virology*, 5, 675-
463 678.
- 464 Lagerqvist, N., Naslund, J., Lundkvist, A., Bouloy, M., Ahlm, C. & Bucht, G. 2009. Characterisation of
465 immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus
466 cDNA constructs. *Virology*, 6, 6.
- 467 Leger, P., Tetard, M., Youness, B., Cordes, N., Rouxel, R. N., Flamand, M. & Lozach, P. Y. 2016.
468 Differential Use of the C-Type Lectins L-SIGN and DC-SIGN for Phlebovirus Endocytosis. *Traffic*, 17,
469 639-56.
- 470 Lopez-Gil, E., Lorenzo, G., Hevia, E., Borrego, B., Eiden, M., Groschup, M., Gilbert, S. C. & Brun, A.
471 2013. A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific
472 CD8+T cell activation and protects immune-competent mice against a lethal RVFV infection. *PLoS*
473 *Negl Trop Dis*, 7, e2309.
- 474 Lopez-Gil, E., Moreno, S., Ortego, J., Borrego, B., Lorenzo, G. & Brun, A. 2020. MVA Vectored
475 Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the
476 Absence of Neutralizing Antibody Responses. *Vaccines (Basel)*, 8.
- 477 Lozach, P. Y., Kuhbacher, A., Meier, R., Mancini, R., Bitto, D., Bouloy, M. & Helenius, A. 2011. DC-
478 SIGN as a receptor for phleboviruses. *Cell Host Microbe*, 10, 75-88.
- 479 McElroy, A. K. & Nichol, S. T. 2012. Rift Valley fever virus inhibits a pro-inflammatory response in
480 experimentally infected human monocyte derived macrophages and a pro-inflammatory cytokine
481 response may be associated with patient survival during natural infection. *Virology*, 422, 6-12.
- 482 Mehand, M. S., Al-Shorbaji, F., Millett, P. & Murgue, B. 2018. The WHO R&D Blueprint: 2018 review
483 of emerging infectious diseases requiring urgent research and development efforts. *Antiviral*
484 *Research*, 159, 63-67.

- 485 Nicholas, D. E., Jacobsen, K. H. & Waters, N. M. 2014. Risk factors associated with human Rift Valley
486 fever infection: systematic review and meta-analysis. *Trop Med Int Health*, 19, 1420-9.
- 487 Niklasson, B. S., Meadors, G. F. & Peters, C. J. 1984. Active and passive immunization against Rift
488 Valley fever virus infection in Syrian hamsters. *Acta Pathol Microbiol Immunol Scand C*, 92, 197-200.
- 489 Paweska, J. T., Mortimer, E., Leman, P. A. & Swanepoel, R. 2005. An inhibition enzyme-linked
490 immunosorbent assay for the detection of antibody to Rift Valley fever virus in humans, domestic
491 and wild ruminants. *Journal of Virological Methods*, 127, 10-18.
- 492 Peters, C. J., Jones, D., Trotter, R., Donaldson, J., White, J., Stephen, E. & Slone, T. W., Jr. 1988.
493 Experimental Rift Valley fever in rhesus macaques. *Arch Virol*, 99, 31-44.
- 494 Seiradake, E., Zhao, Y., Lu, W., Aricescu, A. R. & Jones, E. Y. 2015. Production of cell surface and
495 secreted glycoproteins in mammalian cells. *Methods Mol Biol*, 1261, 115-27.
- 496 Sherman, M. B., Freiberg, A. N., Holbrook, M. R. & Watowich, S. J. 2009. Single-particle cryo-electron
497 microscopy of Rift Valley fever virus. *Virology*, 387, 11-5.
- 498 Smithburn, K. C., Mahaffy, A. F., Haddow, A. J., Kitchen, S. F. & Smith, J. F. 1949. Rift Valley fever;
499 accidental infections among laboratory workers. *J Immunol*, 62, 213-27.
- 500 Vidarsson, G., Dekkers, G. & Rispen, T. 2014. IgG subclasses and allotypes: from structure to
501 effector functions. *Frontiers in immunology*, 5, 520-520.
- 502 Wang, Q., Ma, T., Wu, Y., Chen, Z., Zeng, H., Tong, Z., Gao, F., Qi, J., Zhao, Z., Chai, Y., et al. 2019.
503 Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus. *Nature*
504 *Microbiology*.
- 505 Weingartl, H. M., Zhang, S., Marszal, P., Mcgreevy, A., Burton, L. & Wilson, W. C. 2014. Rift Valley
506 fever virus incorporates the 78 kDa glycoprotein into virions matured in mosquito C6/36 cells. *PLoS*
507 *One*, 9, e87385.
- 508 Wonderlich, E. R., Caroline, A. L., Mcmillen, C. M., Walters, A. W., Reed, D. S., Barratt-Boyes, S. M. &
509 Hartman, A. L. 2018. Peripheral Blood Biomarkers of Disease Outcome in a Monkey Model of Rift
510 Valley Fever Encephalitis. *Journal of Virology*, 92, e01662-17.
- 511 Wright, D., Kortekaas, J., Bowden, T. A. & Warimwe, G. M. 2019. Rift Valley fever: biology and
512 epidemiology. *J Gen Virol*, 100, 1187-1199.


513

514 **FIGURES**



515

516 **Figure 1.** Total IgG titer towards recombinant Gn and Gc correlate strongly with neutralizing
517 antibody titer. (a) Correlations between neutralization titer, as measured by VNT₅₀ assay, and
518 total IgG titer towards Gn and Gc, as measured by ELISA (Gn: $r=0.76$, 95% CI: 0.60-0.86. Gc;
519 $r=0.68$, 95%CI: 0.49- 0.81). **** = $P<0.0001$. (b) Correlations between neutralization titer and
520 avidity of total IgG towards Gn and Gc (Gn: $r=0.37$, 95% CI: 0.09-0.59, **; Gc: $r= 0.08$, 95%CI:
521 -0.21-0.36, $p=0.57$). ** = $P=0.009$. (c) IgG subclass response towards Gn and Gc. Lines
522 represent geometric means.




523



524 **Figure 2.** Neutralizing antibody titers predominantly target RVFV Gn over Gc. Individual sera
 525 were pooled from individuals in Tana River county (n=7) and depleted of anti-Gn antibodies,
 526 anti-Gc antibodies, both or neither. (a) Confirmation of depletion by Gn ELISA (left) and Gc
 527 ELISA (right) with Gn and Gc Endpoint titers of each pool calculated in the table. (b)
 528 Neutralization titer (VNT₅₀) of each depleted pool as a percentage of non-depleted serum
 529 (VNT₅₀ of Gn antibody depletion, 1600; Gc antibody depletion, 5344; Gn+Gc antibody

530 depletion, 1600; non-depleted, 7557). (c) Neutralization titer (FRNT₅₀) after repeating
531 experiment using an entirely different serum pooled from individuals from Kilifi county (n=6).
532



a



b



c




533

534 **Figure 3.** Natural exposure to RVFV elicits a high-titer, long-lived humoral response. Five
535 individuals from Kilifi county (see text) with serum samples spanning 3-11 years were assayed

536 for (a) Neutralization titer, (b) IgG titer of anti-Gn (left) and anti-Gc (right), (c) IgG avidity of
 537 anti-Gn IgG (left) and anti-Gc IgG (right). Year 0 is their earliest available sample, not
 538 necessarily the year of exposure, with subsequent samples plotted relative to that.


539



540

541 **Figure 4.** A low but significant *Ex vivo* IFN γ ELISpot response in naturally exposed individuals.
 542 PBMC from five RVFV-exposed individuals along with 5 case-matched non-exposed controls
 543 were stimulated with an overlapping peptide library spanning the GnGc polyprotein. (a)
 544 Summed responses from the five peptide pools showing significantly higher response in the
 545 naturally exposed group compared to naïve controls (* $P < 0.05$, unpaired *t* test). (b) Responses
 546 to individual peptide pools, dotted line represent the lower limit of detection of 4 SFC/10 6
 547 PBMC for individual pools and 20 SFC/10 6 PBMC for summed responses. SEB stimulated
 548 cells for each volunteer gave >1900 SFC/10 6 PBMC (c) Schematic of the overlapping peptide
 549 library used for stimulation.

550



551

552 **Figure 5.** Top (left) and side views (right) of a schematic surface representation of the
553 pentameric assembly of envelope-displayed RVFV Gn-Gc heterodimers based upon
554 integrative cryoEM and X-ray crystallography (PDB ID: 6F9F)(Halldorsson et al., 2018b) are
555 shown. Pentamers and hexamers of Gn-Gc heterodimers encapsulate RVFV with T=12
556 icosahedral symmetry. Each membrane distally located RVFV Gn is rendered in a shade of
557 purple and each membrane proximally located RVFV Gc is rendered in a shade of blue. The
558 C-terminal regions of RVFV Gn and Gc are shown as lines due to the lack of high resolution
559 structural information and are anchored to the virion membrane (grey).